Sign up to save your podcasts
Or
Share Fred Vogt, Iovance Biotherapeutics
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Fred Vogt, Iovance Biotherapeutics
Send a text
This episode features Fred Vogt, Interim CEO at Iovance Biotherapeutics, recipient of the 2024 Patient Impact Award.
In this episode, Fred shares the journey behind AMTAGVI - the first FDA approved tumor infiltrating lymphocyte (TIL) therapy. Learn about the clinical trial process, how they brought this groundbreaking treatment to market, the impact the Iovance team has on the life sciences industry and how the state of Pennsylvania is supporting Iovance's efforts to treating patients.
View all episodes
By Life Sciences PennsylvaniaSend a text
This episode features Fred Vogt, Interim CEO at Iovance Biotherapeutics, recipient of the 2024 Patient Impact Award.
In this episode, Fred shares the journey behind AMTAGVI - the first FDA approved tumor infiltrating lymphocyte (TIL) therapy. Learn about the clinical trial process, how they brought this groundbreaking treatment to market, the impact the Iovance team has on the life sciences industry and how the state of Pennsylvania is supporting Iovance's efforts to treating patients.